Which methylated genes matter in colitis-to-cancer progression?

The candidate silenced and immune genes highlighted in the project presentation—and what the evidence does and does not show

There is no single “colitis-to-cancer gene”

The project presentation highlights two kinds of signal: a three-gene promoter-hypermethylation panel whose expression was lower in ulcerative-colitis tissue, and a set of hypomethylated immune genes reported in severe UC. They may mark different parts of inflammatory biology, but none has been shown to drive cancer progression by itself.

Candidate genes sit inside interacting immune, epithelial, signaling, and gene-regulatory pathways. This is an original scientific illustration, not a measured pathway from this cohort.

The most directly supported silenced panel

The presentation cites Kang and colleagues’ UC methylation study. The researchers screened 450K methylation arrays in 3 normal-colon controls and 8 UC samples, then performed technical validation in 79 UC samples. Three promoter CpG-island candidates survived their validation:

Gene	What the cited study observed	What can safely be concluded
FAM217B	Promoter hypermethylation in UC and lower RNA expression in tested UC tissue	A candidate UC methylation marker; its role in disease was not established
KIAA1614	The highest reported methylation frequency of the three in the validation series, plus lower expression	Strong panel member in that dataset, not proof of causal silencing in progression
RIBC2	Promoter hypermethylation and reduced expression in tested UC tissue	A reproducible association within that study; biological function remained uncertain

The important result is the methylation–expression relationship: promoter methylation was higher while measured transcription was lower. That is consistent with epigenetic repression. It does not show that losing these transcripts causes UC, dysplasia, or cancer. The authors themselves noted that the genes’ human disease functions were unknown.

Accessible promoter

fewer methyl marks → transcription can proceed

Hypermethylated promoter

dense CpG methylation → reduced transcription may follow

What “silenced” means—and what it does not

Promoter CpG-island hypermethylation can reduce transcription-factor access or recruit proteins associated with compact chromatin. “Silenced” should describe measured low transcription linked to a specific promoter context. It should not be inferred from methylation anywhere in a gene: gene-body methylation, enhancer methylation, and promoter methylation can relate differently to expression.

Nor is an epigenetic mark necessarily permanent. Cell mixture, inflammatory cytokines, tissue repair, medication, and disease activity can all change the measured average. A colon biopsy contains epithelial, stromal, and immune cells; plasma cfDNA mixes DNA from several tissues.

The immune genes highlighted in severe UC

The slides also list IL10, SIGLEC5, CD86, CLMP, NLRP3, and NLRC4 as hypomethylated in severe UC. Hypomethylation means lower methylation at the reported sites—not automatically higher expression. Their broad biological contexts make them plausible inflammation markers:

• IL10 encodes a central anti-inflammatory cytokine that restrains excessive immune responses.
• SIGLEC5 encodes an inhibitory receptor found on innate immune cells and involved in sensing sialylated structures.
• CD86 provides a co-stimulatory signal used by antigen-presenting cells to shape T-cell activation.
• CLMP encodes a cell-adhesion protein relevant to epithelial organization and intestinal development.
• NLRP3 and NLRC4 encode innate immune sensors that can assemble inflammasomes and promote inflammatory cytokine processing.

This set is biologically coherent with immune activation and epithelial stress. It is not a validated cancer panel, and some differences could reflect more immune cells in an inflamed biopsy rather than epigenetic change within the same cell type.

Genes with clearer links to neoplastic progression

The cited paper also summarizes prior evidence for methylation of CDKN2A/p16, CDH1 (E-cadherin), and GDNF in long-standing UC, plus methylated FOXE1/SYNE1 in colitis-associated neoplasia.

Gene/process	Why methylation could matter	Boundary
CDKN2A/p16 · cell-cycle brake	Promoter silencing can weaken control of cell division	A methylated locus is not sufficient to create a tumor
CDH1 · epithelial adhesion	Reduced E-cadherin may weaken tissue architecture and increase invasive potential	Expression and protein localization need direct measurement
GDNF · cell survival/signaling	Altered regulation may change epithelial and neural-support signaling	Context-dependent and not specific to UC-associated cancer
FOXE1 / SYNE1 · candidate neoplasia panel	Methylation has been evaluated as a marker of colitis-associated colorectal neoplasia	Biomarker association is not proof of driver function

How this project should test the genes

1. Preserve methylated and total read counts at every covered CpG.
2. Test loci and regions with a coverage-aware model such as DSS.
3. Require coherent direction across several CpGs in a promoter or regulatory region.
4. Compare tissue with paired plasma detectability; do not treat them as identical specimens.
5. Check whether effects survive adjustment for inflammation, batch, and estimated cell mixture.
6. When possible, pair methylation with RNA or protein evidence before calling a gene silenced.
7. Validate a locked panel in an independent, longitudinal cohort before connecting it to progression risk.

ImportantBest working hypothesis

The FAM217B–KIAA1614–RIBC2 panel is the presentation’s clearest experimentally supported example of promoter hypermethylation associated with reduced transcription in UC. The immune-gene set may reflect severe inflammatory state. Cancer-relevant genes such as CDKN2A and CDH1 provide mechanistic context. Test them as candidate signals—do not assume any is the culprit.

See how colitis reshapes methylation → · Follow progression from colitis to cancer → · Understand the statistics →